Indaptus Therapeutics, Inc. (NASDAQ:INDP - Get Free Report) saw a large drop in short interest in the month of June. As of June 30th, there was short interest totaling 137,594 shares, a drop of 72.1% from the June 15th total of 493,245 shares. Currently, 0.2% of the company's shares are sold short. Based on an average daily volume of 239,554 shares, the days-to-cover ratio is presently 0.6 days.

Indaptus Therapeutics Trading Up 5.2%

Shares of NASDAQ:INDP traded up $0.13 during trading on Friday, reaching $2.63. 59,624 shares of the company traded hands, compared to its average volume of 172,465. The firm has a market capitalization of $297.82 million, a price-to-earnings ratio of -0.17 and a beta of 1.11. Indaptus Therapeutics has a 52-week low of $0.92 and a 52-week high of $12.98. The business's fifty day moving average is $2.53 and its 200-day moving average is $2.38.

Indaptus Therapeutics (NASDAQ:INDP - Get Free Report) last issued its earnings results on Friday, May 15th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($1.87) by $1.64.

Analysts Set New Price Targets

Several research firms have weighed in on INDP. Weiss Ratings reissued a "sell (e+)" rating on shares of Indaptus Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen raised Indaptus Therapeutics to a "hold" rating in a research note on Saturday, June 27th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of "Sell".

Read Our Latest Stock Report on INDP

Institutional Trading of Indaptus Therapeutics

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC acquired a new position in Indaptus Therapeutics, Inc. (NASDAQ:INDP - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 18,997 shares of the company's stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 1.72% of Indaptus Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 7.06% of the company's stock.

About Indaptus Therapeutics

(Get Free Report)

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company's Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus' pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.

Featured Stories

• Five stocks we like better than Indaptus Therapeutics
• 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
• Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
• Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
• This Dividend ETF Choice Could Shape Your Income Strategy Through 2026

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Indaptus Therapeutics Right Now?

Before you consider Indaptus Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indaptus Therapeutics wasn't on the list.

While Indaptus Therapeutics currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here